ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZVRA vs NVCT // RSI-14 & 200D SMA MOMENTUM

Zevra Therapeutics Inc. (NASDAQ) VS. Nuvectis Pharma Inc. (NASDAQ) • 15-METRIC TALLY: ZVRA 5 — NVCT 0
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ZVRA
rsi-technicals
45.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZVRA VS. NVCT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZVRA NVCT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.30% -35.00% +2.70 ZVRA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -0.40% -2.64% +2.24 ZVRA /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ZVRA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 45.7 41.3 +4.38 ZVRA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.9x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $615.2M $605.6M $9.6M ZVRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZVRA REV NVCT REV ZVRA GROSS % NVCT GROSS % ZVRA FCF NVCT FCF
FY 2025 $0 $0 — — -$2.4M -$16.0M
FY 2024 $0 $0 — — -$69.7M -$12.2M
FY 2023 $0 $0 — — -$33.5M -$16.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZVRA // BETA —
NVCT // BETA —